PRECLINICAL VALIDATION OF ANTI-NUCLEAR FACTOR KAPPA B THERAPY AGAINST VESTIBULAR SCHWANNOMA AND NEUROFIBROMATOSIS TYPE II

Massachusetts Eye And Ear Infirmary, Boston MA

Investigators